Both in Pharmaceuticals
Arbutus Biopharma vs Aktis Oncology
Over the past year ABUS returned −12.3% and AKTS returned −32.8%; their daily moves had a correlation of 0.28.
ABUS −12.3% AKTS −32.8%Growth of $1, one year, split-adjusted
| Metric | ABUS | AKTS |
|---|---|---|
| Price | $4.05 | $15.06 |
| Market cap | $802.3M | $837.4M |
| Today | +4.38% | +0.77% |
| 1 month | −9.6% | −15.7% |
| 6 months | −8.4% | −24.8% |
| Year to date | −15.8% | — |
| 1 year | −11.6% | — |
| Revenue growth (YoY) | −90.6% | — |
| Gross margin | 100.0% | 100.0% |
| Net margin | −512.0% | −713.5% |
| P/E (TTM) | 5.2× | — |
| Price / sales | 4.4× | — |
| Net cash | $89.5M | $517.3M |
| Dividend yield | — | — |
| Volatility (60d) | 38.1% | 55.1% |
| Short % of float | 15.6% | 18.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).